Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry
- PMID: 41532642
- DOI: 10.1111/all.70199
Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry
Abstract
Background: Many patients with chronic spontaneous urticaria (CSU) remain symptomatic despite receiving second-generation H1-antihistamines (sgH1-AH). This data analysis from the Chronic Urticaria Registry (CURE) aimed to describe treatment patterns and identify unmet needs in real-world practice.
Methods: CURE is an international, prospective registry of patients with chronic urticaria. Treatment responses were categorized as Urticaria Control Test (UCT) changes from baseline (BL) to 6-month follow-up (FU). Complete response was defined as UCT = 16 with a ≥ 3-point increase.
Results: Data were available from 3995 adult patients with CSU at BL and 1288 at FU with evaluable UCT. After treatment escalation from BL to FU, 5.3% (no treatment to licensed-dose sgH1-AH), 6.0% (licensed-dose sgH1-AH to up-dosed sgH1-AH), and 28.4% (any dose sgH1-AH to omalizumab) achieved complete response. Factors associated with a lower probability of treatment escalation at FU were UCT ≥ 12 and omalizumab treatment at BL (both p < 0.0001). About one-third (28.6%) of patients clinically eligible for escalation at BL (UCT < 12) did not receive step-up treatment (18.0%) or were even stepped down (10.6%) and remained poorly controlled at FU. Factors associated with lack of escalation in this group included younger age (p = 0.014), shorter disease duration (p = 0.071), presence of wheals and angioedema (p = 0.002), better quality of life (p = 0.001), and treatment with up-dosed sgH1-AH (p = 0.031).
Conclusion: Appropriate treatment escalation improves CSU control, although only about a quarter of patients achieve a complete response, indicating the need for novel treatments. Many patients with poorly controlled CSU do not receive guideline-recommended treatment escalation and remain symptomatic on their current treatments, which deserves further attention.
Keywords: antihistamine; chronic spontaneous urticaria; chronic urticaria registry (CURE); real‐world practice; treatment escalation.
© 2026 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
References
-
- M. Maurer, K. Weller, C. Bindslev‐Jensen, et al., “Unmet Clinical Needs in Chronic Spontaneous Urticaria. A GA2LEN Task Force Report,” Allergy 66, no. 3 (2011): 317–330.
-
- J. Fricke, G. Ávila, T. Keller, et al., “Prevalence of Chronic Urticaria in Children and Adults Across the Globe: Systematic Review With Meta‐Analysis,” Allergy 75, no. 2 (2020): 423–432.
-
- P. Kolkhir, H. Bonnekoh, M. Metz, and M. Maurer, “Chronic Spontaneous Urticaria: A Review,” JAMA 332, no. 17 (2024): 1464–1477.
-
- T. Zuberbier, A. H. Abdul Latiff, M. Abuzakouk, et al., “The International EAACI/GA2LEN/EuroGuiDerm/APAAACI Guideline for the Definition, Classification, Diagnosis, and Management of Urticaria,” Allergy 77, no. 3 (2022): 734–766.
-
- M. Sánchez‐Borges, I. J. Ansotegui, I. Baiardini, et al., “The Challenges of Chronic Urticaria Part 1: Epidemiology, Immunopathogenesis, Comorbidities, Quality of Life, and Management,” World Allergy Organization Journal 14, no. 6 (2021): 100533.
Grants and funding
LinkOut - more resources
Full Text Sources
